← All organizations
Highest phase reached
Phase 3
First clinical trial
Feb 1, 1993First marketed drug
Nov 10, 2011First NDA
Nov 10, 2011Last known activity
Apr 27, 2020
Timeline
1960s
- Jan 1, 1964
New York Blood Center— Founded
2010s
- Nov 10, 2011
allogeneic hematopoietic stem cells— NDA Organization
Drugs by trial phase (15 distinct, 13 trials)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Phase 1 (8 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Anemia, Aplastic
- Anemia, Sickle Cell
- Coronavirus Infections
- Genetic Diseases, Inborn
- HIV Infections
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Myelodysplastic Syndromes
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Severe Acute Respiratory Syndrome
- Transfusion Reaction
Marketed drugs (1)
Recent trials (16)
- NCT04348656CollaboratorPhase 3Apr 27, 2020
- NCT04359810CollaboratorPhase 2Apr 21, 2020
- NCT04156893CollaboratorEarly Phase 1Dec 31, 2019
- NCT04156906CollaboratorEarly Phase 1Dec 31, 2019
- NCT03382418Study chairPhase 1Dec 27, 2017
- NCT03056378Lead sponsorPhase 1Jul 1, 2017
- NCT03056378Overall official - principal investigatorPhase 1Jul 1, 2017
- NCT02889133CollaboratorN/AJan 1, 2017
- NCT02566395CollaboratorPhase 3Dec 1, 2014
- NCT02193191CollaboratorPhase 1Sep 1, 2014
- NCT01656603Lead sponsorPhase 2Feb 1, 2012
- NCT01042717Reponsible party - principal investigatorN/AFeb 1, 2010
- NCT01042717Lead sponsorN/AFeb 1, 2010
- NCT00384787Study chairPhase 1Nov 1, 2006
- NCT00212407Lead sponsorEarly Phase 1Feb 1, 1993
Details
- Founded
- New York City, NY, US Jan 1, 1964
- First NDA
- Nov 10, 2011
- Last known activity
- Apr 27, 2020